Tag: endocyte
Novartis Plans to Acquire Endocyte to Expand Expertise in Radiopharmaceuticals
Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics...
Market Trend: Cancer Immunotherapy Destined for Growth
According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at...
What to Expect at the 17th World Conference on Lung Cancer
An estimated 225,000 Americans are expected to be diagnosed with lung cancer this year. Recurrent Small Cell Lung Cancer or accounts for 10%...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
TARGET trial Shows Improved OS in Patients with FR+ Recurrent NSCLC...
The final overall survival (OS) analysis from the Phase IIb TARGET trial evaluating Endocyte's small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in...
Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with...
Interim results from the phase IIb TARGET Trial, presented as Late-Breaking News at the annual meeting of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows improved survival in adenocarcinoma non-small cell lung cancer patients treated the small molecule drug conjugate (SMDC) vintafolide, being developed byEndocyte, in combination with docetaxel (Taxotere®; Sanofi).[1]
Phase II PRECEDENT Trial of Vintafolide in Platinum-Resistant Ovarian Cancer Basis...
Based on trial results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145; Merck and Endocyte), an investigational folate small molecule drug conjugate or SMDC, published in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology, a regulatory application is currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).
